BIOGNOSYS
14.12.2021 16:02:08 CET | Business Wire | Press release
Biognosys, a leading developer and provider of next-generation proteomics technology and solutions, and Thermo Fisher Scientific, the world leader in serving science with innovative technologies, purchasing convenience and pharmaceutical services, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.
The agreement leverages the two companies’ complementary capabilities in mass spectrometry-based proteomics. Biognosys deploys Thermo Fisher Scientific instruments in its state-of-the-art facility for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific™ instruments and workflows.
Biognosys’ Biomarker Discovery services for pharmaceuticals and diagnostics development integrate Thermo Scientific Orbitrap™ and FAIMS Pro™ instruments with Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and Spectronaut™ Data Independent Acquisition (DIA) analysis software to offer unprecedented depth, quantitative precision, and throughput for unbiased discovery. This new and improved solution searches the complete proteome to quantify up to 3,000 of the most relevant proteins in biofluids and more than 10,000 proteins in tissue biopsies.
Andreas Huhmer, PhD, Senior Director Life Sciences Research OMICS Marketing at Thermo Fisher Scientific: “Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth. Their unbiased discovery approach, coupled with their state-of-the-art data analysis capabilities, unlocks possibilities for transformative biomarker discovery.”
Through the companies’ extended co-marketing agreement , laboratories with in-house proteomics facilities have access to efficient, accurate, and scalable mass spectrometry-based proteomics workflows combining Thermo Scientific mass spectrometry instruments with Biognosys’ proteomics data analysis software and kits.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys: “Our agreement with Thermo Fisher Scientific has helped to greatly advance Biognosys’ mission to give researchers a look at every angle of the proteome to unlock discoveries and transform clinical research. Our suite of software and kits uniquely complements Thermo Scientific mass spectrometry instruments and workflows to enable researchers to obtain the best possible data and insights in any proteomics application.”
Biognosys’ leading DIA software solution, Spectronaut, is compatible with Thermo Scientific Orbitrap Exploris™ 480 and Thermo Scientific™ Q Exactive™ instruments.
Biognosys’ SpectroDive™ software for automated mass spectrometry method set-up, signal processing, and analysis of targeted proteomics experiments supports the SureQuant IS-PRM targeted acquisition workflow.
The PQ500™ Reference Peptide Kit from Biognosys can quantify more than 500 proteins in human plasma/serum samples as part of the SureQuant IS-PRM workflow with the Orbitrap Exploris™ 480 mass spectrometer, delivering sensitive and accurate quantitation to drive scientific progress or clinical decision making.
Learn more about the insights that can be uncovered through the Biognosys and Thermo Fisher Scientific partnership from Lukas Reiter’s presentation, “Recent Progress in Blood Proteomics” , during the Thermo Fisher Scientific dinner workshop at ASMS 2021.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press release
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from
Andersen Global udvider sin juridiske virksomhed i Pakistan med et nyt medlemsfirma2.10.2026 22:36:00 CEST | Pressemeddelelse
Andersen Global styrker sin juridiske tilstedeværelse i Pakistan, idet Samdani & Qureshi, der har været samarbejdspartner siden 2021, skifter navn til Andersen Legal in Pakistan og bliver den seneste medlemsvirksomhed, der slutter sig til organisationen. Andersen Legal in Pakistan har hovedkontor i Islamabad og rådgiver både indenlandske og internationale klienter, herunder virksomheder, investorer, finansielle institutioner, offentlige enheder, udviklingsorganisationer og privatpersoner, om juridiske, kommercielle og regulatoriske forhold. Firmaet arbejder også med voldgift og tvistbilæggelse og rådgiver om komplekse transaktioner, investeringer, finansiering, projekter og tvister i Pakistan og på tværs af landegrænser. "Vores tilgang bygger på stærkt engagement fra ledelsen, klar kommunikation og disciplineret analyse med fokus på at levere rådgivning, som vores klienter kan omsætte til handling," sagde Nudrat Ejaz Piracha, partner hos Andersen Legal in Pakistan. "Ved at blive en del
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press release
Appointments expand emnify executive team to accelerate global growth emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press release
Enterprise software veteran to lead Tacton’s united commercial organization and partner expansion worldwide. Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom